Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. - Veljovich DS; Rothe M; Garrett-Mayer E; Ali-Ahmad HM; Naumann RW; Siedel J; Chan JK; Gregory A; Pisick E; Adesunloye B; Arend RC; Bell M; et al. (JCO precision oncology, 2026)